Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases
HER2+ breast cancer patients have an elevated risk of developing brain metastases (BM), despite adjuvant HER2-targeted therapy. The mechanisms underpinning this reduced intracranial efficacy are unclear. We optimised the in situ proximity ligation assay (PLA) for detection of the high-affinity neure...
Main Authors: | Malcolm Lim, Tam H. Nguyen, Colleen Niland, Lynne E. Reid, Parmjit S. Jat, Jodi M. Saunus, Sunil R. Lakhani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/3/533 |
Similar Items
-
Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
by: Ezgi Tulukcuoglu Guneri, et al.
Published: (2022-04-01) -
In situ protein detection for companion diagnostics
by: Gabriela eGremel, et al.
Published: (2013-10-01) -
The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01) -
Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis
by: Xingfa Huo, et al.
Published: (2023-02-01) -
Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
by: Julie Sigrand, et al.
Published: (2016-03-01)